Safety and Effectiveness of an Adjuvant in Improving Immune Response to Hepatitis B Virus Vaccine in HIV Infected Individuals

NCT00272493 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

48

Enrollment

NIH

Sponsor class

Conditions

HIV Infections

Interventions

BIOLOGICAL: Hepatitis B virus vaccine with GM-CSF adjuvant
BIOLOGICAL: Hepatitis B virus vaccine

Sponsor

National Institute of Allergy and Infectious Diseases (NIAID)